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Introduction
Tar DNA-binding protein 43 (TDP-43) regulates multiple aspects 
of RNA metabolism, including RNA stabilization, transcription, 
splicing, and transport (1). TDP-43 binds thousands of RNAs (2, 
3) and, for particular genes, represses nonconserved cryptic exons 
in a species- (4) and cell-type–specific manner (5, 6). Recently, 
2 groups independently found that TDP-43 is required for the 
correct splicing and expression of stathmin-2 (STMN2) (7, 8), a 
microtubule-associated protein involved in axonal regeneration 
(9). As shown schematically in Figure 1, when TDP-43 is present 
and functional, it binds to GU-rich sequences in the first intron 
of the STMN2 transcript, allowing normal splicing of intron 1 and 
repressing the usage of an alternative or cryptic polyadenylation 
site. Reduced TDP-43 binding to STMN2 pre-mRNA, which could 
occur as a result of TDP-43 nuclear depletion, leads to the inclu-
sion of a region within intron 1 (exon 2a) and introduces a prema-
ture stop codon and polyadenylation. This causes the accumula-
tion of a truncated variant of STMN2 that lacks exons 2 through 5.
No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available, 
but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43 
(FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish 
between patients with FTLD-TDP and FTLD-tau. Therefore, we evaluated truncated stathmin-2 (STMN2) as a proxy of 
TDP-43 pathology, given the reports that TDP-43 dysfunction causes truncated STMN2 accumulation. Truncated STMN2 
accumulated in human induced pluripotent stem cell–derived neurons depleted of TDP-43, but not in those with pathogenic 
TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein. In RNA-Seq analyses of human brain 
samples from the NYGC ALS cohort, truncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP-
43 inclusions. Last, we validated that truncated STMN2 RNA was elevated in the frontal cortex of a cohort of patients with 
FTLD-TDP but not in controls or patients with progressive supranuclear palsy, a type of FTLD-tau. Further, in patients with 
FTLD-TDP, we observed significant associations of truncated STMN2 RNA with phosphorylated TDP-43 levels and an earlier 
age of disease onset. Overall, our data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD.
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While approximately 50% of patients with an FTD syndrome 
have underlying TDP-43 pathology, such pathology can, at pres-
ent, only be definitively confirmed at autopsy. Given the efforts to 
develop therapies specific to FTLD pathological subtypes (i.e., FTD 
with TDP-43 vs. tau pathology), there is a clear need for biomarkers 
that discriminate between them. Further, biomarkers for diagno-
sis or prognosis or that can monitor TDP-43 activity in response to 
TDP-43–tailored therapies are also sorely lacking. Although TDP-43 
represents an attractive biomarker candidate to fulfill these needs, 
efforts to develop sufficiently sensitive immunoassays for the detec-
tion of TDP-43 or its pathological forms in biofluids and that reliably 
differentiate between individuals with and without TDP-43 pathol-
ogy have proven disappointing (27). However, nuclear clearance of 
TDP-43, in the absence of TDP-43 inclusions, has been associated 
with neuronal atrophy in patients with FTLD-TDP or ALS-TDP (28), 
suggesting that early mis-splicing events due to TDP-43 loss of func-
tion may represent a robust and early disease biomarker.
We thus propose that the mis-splicing of STMN2 may provide 
a novel strategy for the indirect assessment of TDP-43 dysfunc-
tion. To test this hypothesis, we first validated the STMN2 splic-
ing event in induced pluripotent stem cell–derived (iPSC-derived) 
cortical and motor neurons that were TDP-43 depleted. Then, 
we evaluated whether the truncated STMN2 isoform accumu-
lates in diseases and tissues characterized by TDP-43 pathology 
using data sets from RNA-Seq studies of brain tissues from a large 
cohort of control subjects and of patients with FTD or ALS with or 
without TDP-43 pathology. Furthermore, we measured truncated 
and full-length STMN2 RNA levels in postmortem medial frontal 
cortex tissue from FTLD-TDP, progressive nuclear palsy (PSP), 
and pathologically normal control brains. PSP was selected as the 
disease control, given that TDP-43 pathology is not found in the 
frontal cortex of these patients with FTLD-tau (29). We addition-
Neuronal and glial inclusions of TDP-43 are a pathologi-
cal hallmark of the majority (~97%) of patients with ALS and 
of approximately 50% of cases with the pathological subtype 
of frontotemporal dementia (FTD), known as frontotempo-
ral lobar degeneration–TDP (FTLD-TDP) (1). ALS is a motor 
neuron disease (MND), whereas patients with FTD present 
clinically with 1 or more of the FTD syndromes characterized 
by behavior, executive function, language, and motor impair-
ments (10). TDP-43 abnormalities are proposed to play a direct 
role in these diseases, since mutations in TARDBP, the gene 
that encodes TDP-43, were discovered in sporadic and familial 
ALS and FTD (11, 12). It is also notable that TDP-43 morpholo-
gy and distribution are associated with clinical phenotypes and 
neurodegeneration in key anatomical regions, such as frontal 
and temporal cortices in FTLD-TDP (13). Cells with TDP-43 
pathology feature a redistribution of TDP-43 from the nucle-
us to the cytoplasm, where TDP-43 is ubiquitinated, hyper-
phosphorylated, and cleaved into C-terminal fragments (14). 
Patients with FTLD-TDP can be further classified into differ-
ent pathological subtypes on the basis of the morphology and 
distribution of the TDP-43 inclusions observed (15, 16). These 
can take the form of neuronal cytoplasmic inclusions, dystro-
phic neurites, neuronal intranuclear inclusions, glial inclusions, 
perivascular inclusions, and fine neurites in the hippocampus 
(14, 17–20). At present, 5 subtypes of FTLD-TDP (A–E) have 
been identified (15, 20–23), with types A–C accounting for more 
than 95% of all FTLD-TDP cases (24). FTLD-TDP type A, the 
most common subtype, is characterized by the presence of all 
the inclusion types mentioned above, whereas types B–E are 
characterized by the presence of a predominant inclusion type 
(19, 22). Furthermore, some FTLD-TDP subtypes are associat-
ed with particular mutations (20, 25, 26).
Figure 1. Truncated STMN2 RNA is generated with loss of nuclear TDP-43. Schematic of TDP-43–regulated STMN2 splicing. When TDP-43 is present and 
functional, it binds to GU-rich sequences in the first intron of the STMN2 transcript and allows normal splicing of intron 1. Reduced TDP-43 binding to STMN2 
RNA, from TDP-43 aggregation or depletion from the nucleus, leads to mis-splicing of STMN2 RNA, resulting in the inclusion of a novel exon encoded within 
intron 1 (termed exon 2a) and containing an alternative or cryptic polyadenylation site. The production of this alternative variant of STMN2, which lacks exons 
2 through 5 (referred to as truncated STMN2), is at the expense of full-length STMN2, which is reduced upon TDP-43 downregulation.
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Analyses of bulk brain tissue RNA-Seq data uncover tissue-spe-
cific truncated STMN2 RNA accumulation in diseases characterized 
by TDP-43 pathology. We quantified the expression of full-length 
and truncated STMN2 in the NYGC ALS Consortium RNA-Seq 
data set across multiple neuroanatomical regions and diseases. 
As of March 2020, we were able to examine 11 tissues, with 1659 
RNA-Seq samples from 439 donors matching established criteria 
for inclusion (see Methods). Donors were diagnosed as non-neu-
rological disease controls or as having FTD, ALS, FTD with ALS 
(ALS-FTLD), or ALS with suspected Alzheimer’s disease (ALS-
AD). Patients with FTD were classified on the basis of their neu-
ropathological diagnosis: FTLD-TDP, FTLD-tau, or FTLD with 
mutations in FUS (FTLD-FUS). ALS samples were divided into 
those with a SOD1 mutation (ALS-SOD1) versus those without 
a SOD1 mutation and thus assumed to have TDP-43 patholo-
gy (ALS-TDP). However, pathology confirming the presence of 
TDP-43 mislocalization in patients with ALS-TDP was not sys-
tematically reported (see Methods).
For each sample, we estimated the expression of full-length 
STMN2 using all RNA-Seq reads covering known STMN2 exons, 
whereas the truncated STMN2 isoform was quantified using 
high-confidence spliced RNA-Seq reads that unambiguously 
connected STMN2 exon 1 with the cryptic exon 2a (exon 1–exon 
2a) (Figure 3A). We found that full-length STMN2 was highly 
expressed in both cortical and cerebellar tissues (median tran-
scripts per million [TPM] in frontal cortex = 58.0 and in cere-
bellum = 73.1) compared with expression levels in spinal cord 
(median TPM in lumbar spinal cord = 6.7), presumably because its 
expression is restricted to neurons and because of the higher white 
matter composition in the spinal cord (Supplemental Figure 4).
We then estimated the expression of truncated STMN2 in the 
NYGC ALS cohort in disease groups across tissues. At least 2 reads 
spanning the exon 1–exon 2a junction could be detected in 398 of 
the 1659 samples in the data set (24.0%) (Supplemental Figure 5). 
Samples that expressed the splice junction did so at a median read 
count of 6 (0.13 reads per million) and a maximum read count of 
120 (2.5 reads per million) (Supplemental Figure 6). We therefore 
chose to model truncated STMN2 expression as a binary outcome, 
with a detection threshold of 2 junction reads uniquely mapped 
across the intron boundary.
Truncated STMN2 was present in disease subtypes known to 
have TDP-43 pathology, as it was detected in the frontal cortex of 
82.4% of patients with FTLD-TDP but was absent in those with 
FTLD-FUS or FTLD-tau and in controls (Figure 3B). In ALS lum-
bar spinal cord, we detected truncated STMN2 in 62.2% of patients 
with ALS with presumed TDP-43 pathology (ALS-TDP) but not in 
patients with ALS-SOD1 or in control individuals (Figure 3C).
We observed an exquisite specificity of truncated STMN2 
expression in tissues known to have TDP-43 pathology. In patients 
with FTLD-TDP, for whom frontal cortex, temporal cortex, and 
cerebellum data sets were available, we detected truncated STMN2 
in frontal and temporal cortices but not in cerebellum (Figure 3D). 
In ALS-TDP tissues, which also included hippocampus, temporal 
cortex, motor cortex, occipital cortex, and spinal cord samples, 
truncated STMN2 expression was most prevalent in the spinal 
cord, followed by the motor cortex and frontal cortex, with little 
to no expression detected in the occipital cortex or cerebellum, 
ally evaluated whether truncated STMN2 levels in the medial fron-
tal cortex discriminated between patients with FTLD-TDP and 
control subjects and assessed associations of truncated SMTN2 
with phosphorylated TDP-43 (p–TDP-43) and clinical features.
Results
TDP-43 depletion in human iPSC–derived neurons leads to aberrant 
STMN2 splicing. To confirm recent reports that correct STMN2 splic-
ing requires TDP-43 (7, 8), we used clustered regularly interspaced 
short palindromic repeat inactivation (CRISPRi) to knock down TDP-
43 expression in human iPSC–derived cortical neurons that consti-
tutively express nuclease deactivated Cas9 (dCas9) fused to blue 
fluorescent protein (BFP) and the transcriptional repressor Krüp-
pel-associated box (KRAB) (dCas9-BFP-KRAB) (30). To achieve this, 
cells were transduced with a lentivirus expressing either an sgRNA 
against the transcriptional start site of TARDBP (TDP-43 KD), or a 
control sgRNA predicted not to bind anywhere in the human genome 
(controls). We confirmed silencing of TARDBP RNA by quantitative 
reverse transcription PCR (qRT-PCR) and RNA-Seq (data set labeled 
“a”), which showed TDP-43–KD efficiencies of approximately 50% 
(47.4% for qRT-PCR, 63.9% for RNA-Seq) (Figure 2A). Reduced 
TARDBP levels resulted in significant reductions of full-length 
STMN2 RNA (56.7% for qRT-PCR, 65.5% for RNA-Seq) (Figure 2B) 
and a significant increase in truncated STMN2 RNA (qRT-PCR, 32.3-
fold increase) (Figure 2C) and RNA-Seq (Figure 2D, data set labeled 
“a”) compared with levels in neurons expressing control sgRNA. In 
parallel, we analyzed published RNA-Seq data from Klim et al. on 
iPSC-derived motor neurons in which TARDBP was knocked down 
(7). Knockdown of TARDBP (Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI139741DS1) was confirmed in the Klim data set (data set labeled 
“b”) and, as expected, was accompanied by a reduction in full-length 
STMN2 RNA levels (Supplemental Figure 1B) and an increase in trun-
cated STMN2 RNA levels (Figure 2D, data set labeled “b”).
We also investigated whether disease-causing mutations of 
TARDBP, in the absence of TDP-43 protein mislocalization or a 
reduction of nuclear levels, are sufficient to impact STMN2 splic-
ing. We evaluated truncated STMN2 expression in RNA-Seq data 
from 2 independent studies that used iPSC-derived motor neu-
rons from patients carrying ALS pathogenic TARDBP mutations 
and from control subjects (Supplemental Table 1). In contrast to 
neurons in which TARDBP was downregulated, we observed no 
increase in truncated STMN2 in motor neurons with TARDBP 
mutations (Figure 2D, data sets labeled “c” and “d”). This obser-
vation was consistent with the lack of change in TDP-43 localiza-
tion (Figure 2E), TARDBP RNA levels (Supplemental Figure 2), and 
TDP-43 protein levels (Supplemental Figure 3) in TARDBP-mutant 
motor neurons. Overall, these data suggest that truncated STMN2 
accumulation in iPSC-derived neurons results from a loss of TDP-
43 function due to TDP-43 depletion and not from splicing function 
changes arising from mutations in TARDBP (31). The redistribution 
of TDP-43 from the nucleus and its sequestration into cytoplasmic 
inclusions, a pathological hallmark of FTD and ALS, with and with-
out a genetic link to TARDBP, are consistent with loss-of-function 
mechanisms that would lead to STMN2 mis-splicing and an upreg-
ulation of truncated STMN2 expression and prompted us to further 
examine this in human tissue from FTD and ALS patients.
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Truncated STMN2 RNA expression is elevated in FTLD-TDP fron-
tal cortex. Given that we detected truncated STMN2 RNA in patients 
with FTLD-TDP but not in those with FTLD-FUS or FTLD-tau (Fig-
ure 3B), this aberrant splicing event may provide a means to iden-
tify patients with FTD with marked TDP-43 pathology. To further 
examine the relationship between TDP-43 and STMN2 in patients 
with FTD, we used the NanoString PlexSet platform to systemati-
cally quantify truncated and full-length STMN2 RNA levels in fron-
tal cortex tissue from a cohort of 238 patients with FTD with immu-
nohistologically confirmed TDP-43–immunoreactive inclusions, a 
cohort of 33 cognitively normal controls who were TDP-43 negative 
respectively (Figure 3E and Supplemental Figure 5). As anticipated, 
patients with concurrent FTD and ALS (ALS-FTLD) had truncat-
ed STMN2 expression in frontal and temporal cortices, as well as 
in the motor cortex and spinal cord (Supplemental Figure 7A). In 
contrast, patients with ALS-AD strongly resembled patients with 
ALS-TDP in their truncated STMN2 detection patterns, with most 
truncated STMN2 expression found in spinal cord and reduced or 
no expression in cortical brain regions (Supplemental Figure 7B). 
Together, these findings demonstrate that truncated STMN2 RNA 
is detected in diseases and tissues characterized by TDP-43 pathol-
ogy, supporting its potential as a marker for TDP-43 dysfunction.
Figure 2. Truncated STMN2 RNA is elevated in iPSC-derived neurons with reduced levels of TDP-43. (A–C) iPSC-derived cortical neurons constitutively express-
ing CRISPR inactivation machinery (data set labeled “a”) were transduced with a lentivirus expressing a sgRNA against TARDBP (TDP-43 KD) or a control sgRNA 
(Controls) and subjected to analysis by qRT-PCR (n = 3 TDP-43 KD, n = 3 controls) and/or RNA-Seq (n = 3 TDP-43 KD, n = 4 controls). The graphs show a decrease 
in TARDBP transcripts (A), a reduction of the full-length STMN2 transcript (B), and an increase in the truncated STMN2 transcript (C) upon TDP-43 depletion. (D) 
Detection of STMN2 cryptic exon 2a inclusion expressed as PSI by RNA-Seq in various iPSC-derived neurons: iPSC-derived cortical neurons (data set labeled “a”) 
described above and performed in this study; iPSC-derived motor neurons treated with TARDBP siRNA (TDP-43 KD) or control siRNA (controls) from Klim et al. 
(data set labeled “b”) (n = 6 TDP-43 KD, n = 11 controls) (7); iPSC-derived motor neurons from patients with TARDBP mutations (TDP-43 mut.) or controls from 2 
independent groups in Edinburgh (data set labeled “c”) (n = 7 TDP-43 KD, n = 4 controls) and Oxford (data set labeled “d”) (n = 10 TDP-43 KD, n = 4 controls) (72). 
Data are presented as the mean ± SEM and were normalized to the control groups in A and B (set to 100%). *P < 0.05, ***P < 0.005, and ****P < 0.001, by Stu-
dent’s t test (A–C) or 1-way ANOVA (D). (E) Representative images of iPSC-derived motor neurons from patients with TARDBP mutations and control subjects 
from a group in Oxford (data set labeled “d” in Figure 1D) showed similar nuclear-cytoplasmic distribution of TDP-43 (green) on day 30 of differentiation (DAPI 
in blue, choline acetyltransferase [ChAT] in white). Scale bar: 10 μm. All panels of Figure 2E are reshown in Supplemental Figure 3A. Additional data associated 
with this figure can also be found in Supplemental Figure 3. See also the complete unedited blots in the supplemental material.
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that truncated STMN2 RNA levels were significantly elevated in all 
patients with FTLD-TDP compared with levels in the control sub-
jects without disease or those with PSP disease in both unadjusted 
analysis (P < 0.001) (Figure 4A, Table 2, and Supplemental Table 
2) and analysis adjusted for age at death, sex, and RNA integrity 
number (RIN) (P = 0.009 vs. controls, P < 0.001 vs. patients with 
PSP) (Figure 4A, Table 2, and Supplemental Table 2). We also 
noted that the levels of truncated STMN2 in individuals with PSP 
were significantly lower than those in control subjects (P = 0.028, 
adjusted analyses for age, sex, and RIN), possibly because of the 
neuronal loss in the patients with PSP.
As in all patients with FTLD-TDP combined, truncated STMN2 
RNA levels in the frontal cortex were increased in FTLD-TDP for 
each TDP-43 type (A–D) compared with levels in patients with 
PSP in both unadjusted and adjusted analyses (Table 2 and Sup-
(henceforth referred to as controls), and a cohort of 41 patients with 
PSP (Table 1). The latter cohort of patients were characterized by 
tau pathology and neurodegeneration in the frontal cortex.
As mentioned, FTLD-TDP can be further classified on the 
basis of morphology and distribution of TDP-43 inclusions. As 
such, our cohort of patients with FTLD-TDP were classified into 
different TDP-43 pathological subtypes: 117 patients were type A 
(27 and 34 patients carried a mutation in C9orf72 or GRN, respec-
tively), 66 were type B (21 and 1 carried a mutation in C9orf72 or 
GRN, respectively), 43 were type C (2 and 1 carried a mutation in 
C9orf72 or GRN, respectively), and 2 were type D (both patients 
had VCP mutants) (Table 1). In addition to conducting our anal-
yses of all FTLD-TDP cases combined, we also evaluated wheth-
er truncated STMN2 accumulation was preferentially associated 
with a particular TDP-43 subtype. In the frontal cortex, we found 
Figure 3. Truncated STMN2 RNA is detected in bulk RNA-Seq from FTLD/ALS tissues with TDP-43 pathology. (A) The NYGC ALS Consortium RNA-Seq 
data set was analyzed for the presence of truncated STMN2 transcripts, which were identified by RNA-Seq reads spanning the exon 1–exon 2a splice 
junction. (B–E) Bar graphs represent the proportion of individuals (percentage) with at least 2 reads spanning the exon 1–exon 2a junction. The number of 
individuals for the samples of the indicated tissues/diseases is indicated. (B) Truncated STMN2 was detected in the frontal cortex of patients with FTLD-
TDP but not in control subjects or patients with FTLD-FUS or FTLD-tau. (C) In the lumbar spinal cord of patients with ALS, truncated STMN2 RNA was only 
detected in ALS-TDP samples but not in ALS-SOD1 or control samples. (D) Among FTLD-TDP tissues, truncated STMN2 was only detected in those known 
to have TDP-43 pathology (frontal and temporal cortex), whereas (E) within ALS-TDP tissues, truncated STMN2 RNA was seen in motor cortex and spinal 
cord tissues but not in regions without TDP-43 pathology.
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plemental Table 2). Compared with controls, truncated STMN2 
levels were significantly increased in patients with FTLD-TDP 
types A, B, and C, but not in those with type D, in unadjusted anal-
yses (Table 2 and Supplemental Table 2), although the levels only 
in those with type A FTLD-TDP remained significant in analyses 
adjusted for age, sex, and RIN (Table 2 and Supplemental Table 2).
We observed that truncated STMN2 levels in the frontal cortex 
discriminated between the patients with FTLD-TDP and the PSP 
control subjects, with an area under the receiver operating charac-
teristic curve (AUC) of 0.76 (95% CI = 0.69–0.84) (Table 2). Frontal 
cortex truncated STMN2 also discriminated between FTLD-TDP 
patients and cognitively normal controls with a more modest AUC 
of 0.67 (95% CI = 0.57–0.78) (Supplemental Table 2). Further-
more, truncated STMN2 levels similarly discriminated between 
controls (cognitively normal or PSP disease controls) and patients 
with FTLD-TDP of all TDP-43 types, most prominently for types 
A, C, and D (Table 2 and Supplemental Table 2). In contrast, trun-
cated STMN2 levels did not effectively distinguish patients with 
PSP from control subjects (AUC: 0.60, 95% CI = 0.47–0.73).
The increase in truncated STMN2 levels in FTLD-TDP fron-
tal cortex was paired with a decrease in full-length STMN2 levels 
(P < 0.001) (Figure 4B and Supplemental Table 3). Of interest, full-
length STMN2 expression was also decreased in patients with PSP 
compared with expression levels in controls (P < 0.001) (Figure 
4B and Supplemental Table 3), probably because of neurodegen-
eration in this region. Full-length STMN2 levels also distinguished 
control subjects from patients with FTLD-TDP (AUC: 0.74) 
and PSP (AUC: 0.83), but were not as effective in distinguishing 
patients with FTLD-TDP from those with PSP (AUC: 0.60, 95% 
CI = 0.51-0.68; Supplemental Table 3).
Taken together, our data show that truncated STMN2 RNA 
levels were significantly elevated in patients with FTLD-TDP 
compared with levels in controls and may be used to distinguish 
FTD patients with TDP-43 pathology from both cognitively nor-
mal individuals and disease controls.
Truncated STMN2 RNA associates with p–TDP-43 burden in the 
frontal cortex of patients with FTLD-TDP. That truncated STMN2 
levels were elevated in the frontal cortex of patients with FTLD-
TDP but not in those with PSP (Figure 4A) or other forms of FTLD 
(FTLD-tau, FTLD-FUS) or ALS (ALS-SOD1) (Figure 3) suggests 
that truncated STMN2 production is caused by a loss of TDP-43 
nuclear function resulting from its mislocalization to the cyto-
plasm and/or its sequestration into inclusions — hallmark features 
of FTLD-TDP. To evaluate this possibility further, we examined 
whether full-length or truncated STMN2 RNA levels in the fron-
tal cortex correlated with p–TDP-43 accumulation. To this end, 
we prepared urea-soluble protein lysates from the same tissues 
used to measure STMN2 isoforms and quantified p–TDP-43 in 
these lysates using a previously described immunoassay (32–34). 
Although the levels of full-length STMN2 did not associate with 
p–TDP-43 levels (β: 0.02, P = 0.53) (Supplemental Table 4), higher 
p–TDP-43 levels were associated with higher truncated STMN2 RN 
A levels (Figure 4C) in both unadjusted analyses (β: 0.20, 
P < 0.001) (Table 3) and in a multivariable analysis adjusted for 
age, sex, and TDP-43 subtype (β: 0.19, P < 0.001) (Table 3). Tak-
en together, our data suggest that truncated STMN2 RNA, but not 
full-length STMN2, accumulates in brain regions marked by TDP-
43 pathology and associates with p–TDP-43 burden.
Truncated STMN2 RNA levels associate with an earlier age of 
FTLD-TDP onset. We additionally examined whether truncated or 
full-length STMN2 levels in the frontal cortex associate with clinical 
characteristics of individuals with FTLD-TDP. We found a significant 
inverse correlation between truncated STMN2 RNA levels and age at 
disease onset (Figure 4D) in analyses, adjusting for sex, age at death, 
and TDP-43 type and after correcting for multiple testing (P = 0.005) 
(Table 3). However, survival after onset did not associate with trun-
cated STMN2 RNA levels, after correcting for age at onset, sex, and 
TDP-43 subtype (P = 0.32) (Table 3). Of interest, we observed a nom-
inal but not statistically significant association with lower truncated 
STMN2 levels in males (β: –0.35, P = 0.034 in adjusted analyses for 
age and TDP-43 type) (Supplemental Table 4). In contrast, full-length 
STMN2 levels failed to associate with clinical features of FTLD-TDP, 
including age of onset and survival (Supplemental Table 4).
Discussion
FTLD, the neuropathological substrate of FTD, is the second 
most common cause of early-onset dementia (35). Although no 
effective treatment is available, several therapeutic approaches 







FTLD-TDP type A 
(n = 117)
FTLD-TDP type B 
(n = 66)
FTLD-TDP type C 
(n = 43)
FTLD-TDP type D 
(n = 2)


















Survival after onset (yr) NA 7.0 (4.0, 14.0) 7.0 (0.6, 25.0) 7.0 (1.0, 25.0) 4.0 (0.6, 20.0) 10.6 (4.0, 25.0) 8.5 (7.0, 10.0)
Age at onset (yr) NA 61.5 (46.0, 79.5) 64.5 (40.0, 85.8) 67.8 (40.0, 85.8) 61.4 (44.0, 85.7) 62.7 (46.0, 76.0) 54.1 (54.0, 54.2)
RIN 9.6 (7.1, 10.0) 9.5 (7.1, 10.0) 9.5 (7.0, 10.0) 9.4 (7.0, 10.0) 9.6 (7.0, 10.0) 9.5 (7.8, 10.0) 9.9 (9.8, 10.0)
The sample median (minimum, maximum) is given for continuous variables. Information was unavailable regarding TDP-43 subtype (all FTLD-TDP: n = 10), 
age at death (all FTLD-TDP: n = 1), p–TDP-43 burden in the frontal cortex (all FTLD-TDP: n = 1), survival after onset (PSP: n = 4; all FTLD-TDP: n = 20), and age 
at onset (PSP: n = 4; all FTLD-TDP: n = 20). Among the patients with FTLD-TDP, 50 had C9orf72 mutations (n = 27 TDP-43 type A, n = 21 TDP-43 type B, n = 2 
TDP-43 type C), 36 had GRN mutations (n = 34 TDP-43 type A, n = 1 TDP-43 type B, n = 1 TDP-43 type C), and 2 had VCP mutations (TDP-43 type D).
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
6 0 8 6 jci.org   Volume 130   Number 11   November 2020
are being investigated to target TDP-43 and tau, the 2 proteins 
most commonly associated with the major pathological FTLD 
subtypes. Their testing in clinical trials, however, faces a consid-
erable barrier: our inability to determine the underlying protein 
pathology in living patients with FTD. Although the pathomech-
anisms driven by TDP-43 and tau differ, the clinical symptoms of 
FTD patients with TDP-43 or tau pathology overlap. Ultimately, 
this hinders the selection of patients with sporadic FTD who are 
suitable for a particular clinical trial. Since there is a clear need 
for biomarkers to identify FTD patients with TDP-43 pathology, 
we evaluated whether truncated STMN2 could serve as a proxy 
for TDP-43 pathology. Using RNA-Seq and RNA quantification 
techniques, we show that truncated STMN2 RNA levels were 
elevated in human iPSC–derived neurons depleted of TDP-43 
and in bulk tissue from FTD and ALS patients with TDP-43 
pathology. We did not detect truncated STMN2 in iPSC-derived 
neurons with pathogenic TARDBP mutations where no change 
in TDP-43 levels, localization, or aggregates was detected, sup-
porting the fact that loss of TDP-43 nuclear function, and not 
splicing changes induced by pathogenic mutations, were driv-
ing this event. We were unable to assess postmortem tissue 
from patients carrying TARDBP mutations, which are rare in 
the FTD and ALS populations, as a group, but given that these 
patients develop florid TDP-43 pathology, we expected trun-
cated STMN2 to be present at levels similar to those in patients 
with sporadic ALS or FTLD-TDP. Additionally, we found that 
truncated STMN2 RNA accumulated in the frontal cortex of 
patients with FTLD-TDP but not in control subjects or patients 
with PSP and was significantly correlated with p–TDP-43 levels 
and an earlier age of disease onset. Taken together, our data 
support the notion that truncated STMN2 production results 
from TDP-43 loss of function.
Figure 4. Truncated STMN2 is elevated in FTLD-TDP and associates with higher p–TDP-43 burden and earlier age of FTD onset. (A and B) Truncated and full-
length STMN2 levels were measured in RNA extracted from frontal cortex of control subjects and FTLD-TDP and PSP patients, using the NanoString PlexSet 
platform. (A) A significant accumulation of truncated STMN2 RNA was detected in patients with FTLD-TDP but not in controls (see also Supplemental Table 2) 
or patients with PSP (see also Table 2). (B) Full-length STMN2 levels were significantly decreased in FTLD-TDP and PSP patients (see also Supplemental Table 
3). Data are presented as the median with a 95% CI, and P values were determined using linear regression models that were adjusted for age at death, sex, 
and RIN. *P < 0.05, ***P < 0.005, ****P < 0.001. (C and D) In our FTLD-TDP cohort (n = 238), significant correlations were observed between truncated STMN2 
RNA levels and (C) a higher burden of p–TDP-43 and (D) an earlier age of disease onset. See Table 3 for the correlation coefficients.
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logical changes in TDP-43. In line with this, we observed a sig-
nificant association of truncated STMN2 RNA with p–TDP-43 
protein levels (P < 0.001, Table 3), which remained statistical-
ly significant after controlling for multiple variables (age, sex, 
and TDP-43 subtype; P < 0.001, Table 3). However, it is possible 
that p–TDP-43 levels alone may not be a perfect corollary for 
nuclear TDP-43 depletion. Of interest, the levels of truncated 
STMN2 RNA did not differ among different TDP-43 subtypes, 
suggesting that truncated STMN2 levels are elevated in all types 
of TDP-43 pathology.
Importantly, higher truncated STMN2 RNA levels in the fron-
tal cortex at death were significantly associated with an earlier age 
at disease onset (P = 0.005, Table 3), but we found no association 
with survival after disease onset. Given that truncated STMN2 
RNA serves as a proxy for TDP-43 dysfunction, this earlier age 
of onset in patients with higher postmortem truncated STMN2 
RNA levels could point to more severe defects in RNA metabo-
lism resulting from aberrant TDP-43 function, including loss of 
STMN2 function.
Strengths of our study include the use of samples from a clini-
cally well-characterized, immunohistologically confirmed cohort 
of 238 patients with FTLD-TDP from which high-integrity RNA 
was extracted from the frontal cortex, and the use of quantitative 
measurements of truncated STMN2 RNA and p–TDP-43 protein. 
Moreover, we evaluated multiple neuroanatomical regions in bulk 
tissue RNA-Seq from a large data set that included 1659 FTD and 
ALS patients with and without TDP-43 pathology. Further, our 
study also used 3 different approaches (RNA-Seq, NanoString, 
and qRT-PCR, the latter of which was also performed to validate 
truncated STMN2 in patients with FTLD-TDP, as shown in Sup-
plemental Figure 9) that have different sensitivity and specificity 
linked to the methodology but that all detect significant differ-
ences in truncated STMN2, highlighting the reproducibility of the 
finding. Our study also has some limitations. While we specifically 
designed our study to evaluate truncated STMN2 as a marker of 
TDP-43 pathology — information important to establish its value 
as a candidate biomarker — we did not measure the translation 
product from this truncated variant because of a lack of com-
mercially available antibodies. At present, it is unclear whether 
As mentioned above, 2 independent reports recently revealed 
that TDP-43 regulates STMN2 expression and that TDP-43 deple-
tion produces a truncated, nonfunctional STMN2 variant (7, 8). 
Increased truncated STMN2 RNA levels were detected in spinal 
cord tissue of 17 patients with ALS but not in that of 6 controls, and 
ISH studies found truncated STMN2 RNA in lower and upper motor 
neurons in 5 patients with ALS (8). We thus evaluated truncated 
STMN2 as a proxy TDP-43 activity marker for FTD using postmor-
tem RNA-Seq data across 11 tissues available from a large cohort 
of FTD, ALS, and FTLD-ALS patients. Notably, our RNA-Seq anal-
yses detected the STMN2 cryptic exon that gives rise to truncated 
STMN2 only in FTD and ALS patients with TDP-43 pathology. In 
addition, the presence of abnormal STMN2 was highly specific to 
brain regions characterized by TDP-43 pathology.
In addition to our analyses of RNA-Seq data, we directly 
measured truncated STMN2 RNA in postmortem frontal cortex 
tissue from patients with FTLD-TDP, which again revealed an 
aberrant accumulation of truncated STMN2 in comparison with 
controls and individuals with PSP. In fact, we found that truncated 
STMN2 RNA levels distinguished between patients with FTLD-
TDP and those with PSP, with an area under the ROC curve of 
0.76. As anticipated, truncated STMN2 accumulation in patients 
with FTLD-TDP was accompanied by a decrease in full-length 
STMN2, as was observed in cell culture models (7, 8). Full-length 
STMN2 was also decreased in patients with PSP, which were con-
firmed to lack TDP-43 pathology. Given that STMN2 is expressed 
by neurons and its expression is abundant in the frontal cortex, the 
decrease in full-length STMN2 in patients with PSP likely reflects 
neurodegenerative neuronal loss. Indeed, a recent report found 
that full-length STMN2 RNA levels were also decreased in the 
brains of patients with Parkinson’s disease (36), possibly arguing 
for the use of STMN2 levels as a neurodegenerative disease bio-
marker. It is also possible that, aside from TDP-43, various other 
factors regulate full-length STMN2 expression. This could explain 
why full-length STMN2 levels did not correlate with p–TDP-43 
burden or with clinical features.
The accumulation of truncated STMN2 RNA in the frontal 
cortex of patients with FTLD-TDP but not of patients with PSP 
indicates that truncated STMN2 production is caused by patho-
Table 2. Comparisons of truncated STMN2 RNA in frontal cortex between patients with FTLD-TDP and patients with PSP.
Unadjusted analysis Adjusting for age at death, sex, and RIN
Group n Median (minimum, maximum)  
levels of truncated STMN2 RNA
Regression coefficient  
(95% CI)
P value Regression coefficient 
(95% CI)
P value AUC (95% CI)  
vs. PSP cases
PSP 41 217 (22, 880) 0.00 (reference) NA 0.00 (reference) NA NA
All FTLD-TDP 238 560 (8, 5210) 1.38 (0.96, 1.80) < 0.001 1.36 (0.95, 1.77) < 0.001 0.76 (0.69, 0.84)
FTLD-TDP type A 117 595 (8, 3495) 1.47 (0.98, 1.95) < 0.001 1.37 (0.87, 1.86) < 0.001 0.78 (0.70, 0.86)
FTLD-TDP type B 66 494 (62, 5210) 1.28 (0.77, 1.79) < 0.001 1.29 (0.79, 1.78) < 0.001 0.74 (0.65, 0.84)
FTLD-TDP type C 43 575 (106, 2071) 1.34 (0.79, 1.89) < 0.001 1.26 (0.73, 1.78) < 0.001 0.77 (0.66, 0.87)
FTLD-TDP type D 2 1035 (1008, 1062) 2.40 (0.25, 4.55) 0.029 3.07 (1.07, 5.07) 0.004 1.00 (1.00, 1.00)
Regression coefficients, 95% CIs, and P values were determined using linear regression models, where the levels of truncated STMN2 RNA in the frontal 
cortex were considered on the base 2 logarithmic scale. Regression coefficients were interpreted as the difference in mean levels of truncated STMN2 RNA 
in the frontal cortex (on the base 2 logarithmic scale) between the given group of patients with disease and patients with PSP. P values of 0.010 or less 
were considered statistically significant after applying a Bonferroni’s correction for multiple testing.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
6 0 8 8 jci.org   Volume 130   Number 11   November 2020
AD develop TDP-43 inclusions, and, compared with AD patients 
without TDP-43 pathology, they are cognitively and functionally 
worse, suggesting that abnormal TDP-43 causes a modified AD 
phenotype (37–46). Our work also highlights how future means to 
detect truncated STMN2 RNA or protein in biofluids may provide 
important information on disease activity and therefore be useful 
in assessing drug efficacy in clinical trials. Thus, these endeavors 
are expected to increase the likelihood of success in developing 
effective therapeutics and improving the care of patients with 
TDP-43 proteinopathies.
Methods
RNA extraction, complementary DNA synthesis, and qRT-PCR in iPSC-de-
rived neurons. iPSC-derived neurons were harvested, and cell pellets were 
lysed in TRI reagent (Zymo Research). Then, total RNA was extracted fol-
lowing the manufacturer’s instructions using the Direct-zol RNA Miniprep 
Kit (Zymo Research), and 850 ng RNA was used for RT-PCR. RT-PCR of 
RNA samples was performed using the High Capacity cDNA Transcrip-
tion Kit with random primers (Applied Biosystems), and qRT-PCR was 
performed using SYBR GreenER qPCR SuperMix (Invitrogen, Thermo 
Fisher Scientific). Samples were run in triplicate, and qRT-PCRs were run 
on a Prism 7900HT Fast Real-Time system (Applied Biosystems). Relative 
quantification was determined using the ΔΔCt method and normalized to 
the endogenous controls RPLP0 and GAPDH. The following primers and 
their sequences were used: STMN2 forward: 5′-AGCTGTCCATGCT-
GTCACTG-3′, STMN2 reverse: 5′-GGTGGCTTCAAGATCAGCTC-3′; 
truncated STMN2 forward: 5′-GGACTCGGCAGAAGACCTTC-3′, trun-
cated STMN2 reverse: 5′-GCAGGCTGTCTGTCTCTCTC-3′; TARDBP 
forward: 5′-AATTCTGCATGCCCCAGA-3′, TARDBP reverse: 5′-GAAG-
CATCTGTCTCATCCATTTT-3′; GAPDH forward: 5′-GTTCGACAGT-
CAGCCGCATC-3′, GAPDH reverse: 5′-GGAATTTGCCATGGGTG-
GA-3′; and RPLP0 forward: 5′-TCTACAACCCTGAAGTGCTTGAT-3′, 
RPLP0 reverse: 5′-CAATCTGCAGACAGACACTGG-3′.
the predicted peptide of only 16 amino acids is translated from 
truncated STMN2 RNA. Nevertheless, our findings indicate that 
the development of novel tools (antibodies, immunoassays) for 
the detection of truncated STMN2 protein and additional stud-
ies to evaluate the role of truncated STMN2 RNA and protein in 
disease pathogenesis and as biomarkers are well merited. Criti-
cal next steps to hasten the translation of this finding to the clinic 
include determining whether truncated STMN2 RNA or protein 
is detected in the biofluids of patients with FTD (e.g., spinal flu-
id and blood) and, if so, whether they discriminate between FTD 
subtypes (i.e., with or without TDP-43). Although expression of 
truncated STMN2 in affected postmortem tissues can distinguish 
FTLD-TDP from PSP cases, which has important implications, as 
it supports truncated STMN2 as a viable proxy for the presence of 
TDP-43 pathology, the ability to discriminate between FTLD-TDP 
and PSP patients was only modest (AUC: 0.76). RNA degradation 
invariably occurs in postmortem brain tissues, possibly contrib-
uting to this modest AUC and potentially pointing toward the 
possibility of detecting truncated STMN2 in CSF or blood, which 
are typically frozen immediately after collection, to discriminate 
between patient groups. Nonetheless, sensitive methods will be 
needed to detect truncated STMN2 RNA and/or protein in human 
biofluids. Additionally, determining at what point during the 
course of disease truncated STMN2 levels begin to be upregulat-
ed will have to be evaluated and will probably require longitudinal 
collections of CSF and blood first from patients with ALS, who are 
almost certain to develop TDP-43 pathology, and then from indi-
viduals with FTD or FTD/ALS harboring genetic variants associ-
ated with TDP-43 dysfunction.
If, as anticipated, truncated STMN2 RNA or protein is detect-
ed in the biofluids of FTD patients with TDP-43 pathology, it may 
have the potential to similarly identify those patients with AD 
who have TDP-43 pathology. Indeed, up to 67% of patients with 
Table 3. Associations of truncated STMN2 with p–TDP-43 and clinical characteristics in FTLD-TDP frontal cortex
Association with frontal cortex truncated STMN2 RNA
Unadjusted analysis Multivariable analysis
Variable Regression coefficient 
(95% CI)
P value Regression coefficient 
(95% CI)
P value Multivariable model adjustments
p–TDP-43 (doubling) 0.20 (0.12, 0.28) < 0.001 0.19 (0.09, 0.28) < 0.001 Age at death, sex, TDP-43 subtype
TDP-43 subtype Overall test of difference: P = 0.48 Overall test of difference: P = 0.33 Age at death and sex
FTLD-TDP type A 0.00 (reference) NA 0.00 (reference) NA  
FTLD-TDP type B –0.19 (–0.57, 0.19) 0.33 –0.31 (–0.72, 0.10) 0.14  
FTLD-TDP type C –0.13 (–0.56, 0.31) 0.57 –0.16 (–0.60, 0.27) 0.46  
FTLD-TDP type D 0.93 (–0.91, 2.77) 0.32 0.68 (–1.17, 2.53) 0.47  
Age at onset (10-yr increase) –0.23 (–0.41, –0.04) 0.015 –0.29 (–0.49, –0.09) 0.005 Sex and TDP-43 subtype 












Age at death and TDP-43 subtype 
Regression coefficients, 95% CIs, and P values were determined using linear regression models, where frontal cortex truncated STMN2 RNA was 
considered on the base 2 logarithmic scale. Regression coefficients were interpreted as the change in mean frontal cortex truncated STMN2 RNA (on 
the base 2 logarithmic scale) corresponding to the presence of the indicated characteristic (categorical variables) or the increase shown in parentheses 
(continuous variables). P values of 0.010 or less were considered statistically significant after applying a Bonferroni’s correction for multiple testing.
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RNA-Seq samples were subjected to quality control modeled on 
the criteria of the Genotype Tissue Expression Consortium (64). Any 
sample failing 1 of the following sequencing metric thresholds was 
removed: a unique alignment rate of less than 90%, ribosomal bases 
of greater than 10%, a mismatch rate of greater than 1%, a duplica-
tion rate of greater than 0.5%, intergenic bases of less than 10.5%, and 
ribosomal bases of greater than 0.1%. Sex was verified using XIST and 
UTY expression. Tissue identity was confirmed using the expression 
of the cerebellar marker CBNL1 and the cortical marker NRGN. Spinal 
cord samples were confirmed by expression of the oligodendrocyte 
marker MBOP. Following quality control, 1905 samples of 1924 were 
retained for analysis. When comparing subgroups and tissues, only 
tissues with at least 50 samples and disease subgroups with at least 4 
individuals were kept for analysis. This resulted in 1659 samples from 
11 tissues and 439 donors.
Expression of the full-length STMN2 isoform was estimated 
using RSEM, summing the estimates of the 3 annotated isoforms 
in GENCODE, version 30, into a gene-level estimate of expression 
normalized in terms of TPM. Given the large size of the NYGC ALS 
cohort, RNA-Seq data were produced on 2 different sequencing plat-
forms. Exploratory analyses showed a substantial batch effect in gene 
expression due to the 2 sequencing platforms. We therefore split the 
data set by sequencing platform, along with tissue and disease status. 
A comparison of ALS-TDP and non-neurological controls revealed 
that STMN2 had an inconsistent pattern of differential expression, 
with no tissue showing a marked difference in either platform (Sup-
plemental Figure 4A). In addition, RNA degradation is known to 
affect the estimation of transcript abundance (65, 66), and we rea-
soned that systematic differences in RNA quality among samples 
sequenced on different platforms and between disease and control 
groups or tissues could confound our estimation of STMN2 expres-
sion. We compared the RIN values for each sample between the ALS-
TDP and control groups and found significant differences in RIN 
values in some comparisons (Supplemental Figure 4B). The small 
number of controls available limited further comparisons in some tis-
sues. We then correlated the RIN with STMN2 expression and found 
a positive correlation in multiple tissues and on both sequencing plat-
forms (Supplemental Figure 4C).
Quantifying STMN2 splicing from RNA-Seq data. For downstream 
analysis of STMN2 splice junction reads, a bioinformatics pipeline was 
created using Snakemake (67, 68). Uniquely mapped reads within the 
STMN2 locus were extracted from each sample using SAMtools. Any 
read marked as a PCR duplicate by Picard Tools was discarded. Splice 
junction reads were then extracted with RegTools (69) using a mini-
mum of 8 bp as an anchor on each side of the junction and a maximum 
intron size of 500 kb. Junctions from each sample were then clustered 
together using LeafCutter (70) with relaxed junction filtering (minimum 
total reads per junction = 30, minimum fraction of total cluster reads = 
0.0001). This produced a matrix of junction counts across all samples. 
Using coordinates from the Klim (7) and Melamed (8) publications, the 
TDP-43–associated junction of the novel truncated STMN2 isoform was 
extracted from the matrix. A detection threshold of 2 or more unique-
ly mapped reads was applied. We found no association between trun-
cated STMN2 detection and RIN, sequencing platform, or total library 
size (Supplemental Figure 8, A–C). The relationship between expression 
levels of full-length and truncated STMN2 was complex, with no overall 
detection of association across tissues (Supplemental Figure 8D).
RNA-Seq analyses from iPSC-derived neurons. Data from Klim et 
al. (7) were downloaded from the NCBI’s Gene Expression Omnibus 
(GEO) database (GEO GSE121569). All iPSC cells lines were analyzed 
with the same analysis pipeline. Raw FASTQ files were trimmed using 
fastp (47) and aligned to the hg38 build (GRCh38.primary_assembly) 
of the human reference genome using STAR (2.7.2a) (48). Gene abun-
dance for TARDBP and STMN2 was calculated with featureCounts (49) 
using gene models from GENCODE GTF, version 31, and converted to 
reads per kilobase per million (RPKM) using edgeR (50). The relative 
abundance of truncated STMN2 as a proportion of total STMN2 was 
expressed in terms of percent spliced in (PSI) (51). This was calculated 
by parsing the splice junction tables from STAR and taken as the per-
centage of all uniquely mapped STMN2 junction reads from exon 1 to 
exon 2a over the sum of all junction reads coming from exon 1.
NYGC ALS Consortium cohort. Patients with FTD were classi-
fied according to a pathologist’s diagnosis of FTD with TDP-43 
inclusions (FTLD-TDP), tau inclusions (FTLD-tau), or FUS inclu-
sions (FTLD-FUS). ALS samples were divided into the following 
subcategories using the available Consortium metadata: ALS with 
or without reported SOD1 mutations (ALS-TDP and ALS-SOD1); 
ALS with frontotemporal dementia (ALS-FTLD); and ALS with 
AD (ALS-AD). All non-SOD1 ALS samples were grouped as “ALS-
TDP” in this work for simplicity, although reporting of postmortem 
TDP-43 inclusions was not systematic and therefore not integrated 
into the metadata. Confirmed TDP-43 pathology postmortem was 
reported for all FTLD-TDP samples.
NYGC ALS Consortium RNA-Seq library preparation from bulk tis-
sue RNA. The Consortium’s sample processing has been, in part, pre-
viously described (52). In brief, RNA was extracted from flash-frozen 
postmortem tissue using TRIzol (Thermo Fisher Scientific) chloro-
form, followed by column purification (RNeasy Minikit, QIAGEN). 
RIN was assessed on a Bioanalyzer (Agilent Technologies). RNA-
Seq libraries were prepared from 500 ng total RNA using the KAPA 
Stranded RNA-Seq Kit with RiboErase (KAPA Biosystems) for rRNA 
depletion and Illumina-compatible indexes (NEXTflex RNA-Seq Bar-
codes, NOVA-512915, PerkinElmer, and IDT for Illumina TruSeq UD 
Indexes, 20022370). Pooled libraries (average insert size: 375 bp) 
passing the quality criteria were sequenced either on an Illumina HiS-
eq 2500 (125 bp paired end) or an Illumina NovaSeq (100 bp paired 
end). Samples were subjected to extensive sequencing and RNA-Seq 
quality control metrics at the NYGC that are described below. Nota-
bly, a set of more than 250 markers was used to confirm tissue, neu-
roanatomical regions, and sex in the RNA-Seq data. Samples passing 
these metrics are available for distribution. The samples had a median 
sequencing depth of 42 million read pairs, with a range between 16 
and 167 million read pairs.
Analyses of bulk tissue RNA-Seq data. Samples were uniformly 
processed using RAPiD-nf, an efficient RNA-Seq processing pipeline 
implemented in the NextFlow framework (53). Following adapter 
trimming with Trimmomatic (version 0.36) (54), all samples were 
aligned to the hg38 build (GRCh38.primary_assembly) of the human 
reference genome using STAR (2.7.2a) (48), with indexes created from 
GENCODE, version 30 (55). Gene expression was quantified using 
RSEM (1.3.1) (56). Quality control was performed using SAMtools (57) 
and Picard Tools (58), and the results were collated using MultiQC 
(59). Exploratory plots were created in R, version 3.6.0 (60), using 
dplyr, tidyr, stringr, ggplot2, patchwork, and ggpubr packages (61–63).
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performed for the separate FTLD-TDP versus control and FTLD-
TDP versus PSP analyses, after which P values of less than 0.01 were 
considered statistically significant.
In a secondary analysis, we compared truncated STMN2 RNA lev-
els between controls and patients with PSP and made pairwise com-
parisons of full-length STMN2 RNA and p–TDP-43 (both on the base 
2 logarithmic scale) between controls, patients with PSP, and patients 
with FTLD-TDP using the aforementioned linear regression analyses.
In the subgroup of 238 patients with disease, associations of 5 dif-
ferent variables (p–TDP-43 levels, TDP-43 subtype, age at onset, sur-
vival after onset, and sex) with both truncated and full-length STMN2 
RNA levels were evaluated using single-variable and multivariable lin-
ear regression models, where truncated and full-length STMN2 RNA 
levels in the frontal cortex were assessed on the base 2 logarithmic 
scale, and multivariable models were adjusted for predefined, poten-
tially confounding variables. The multivariable model assessing the 
p–TDP-43 response in frontal cortex was adjusted for age at death, sex, 
and TDP-43 subtype. The multivariable model assessing TDP-43 sub-
type was adjusted for sex and age at death. The multivariable model 
assessing age at onset was adjusted for sex and TDP-43 subtype. The 
multivariable model assessing survival after onset was adjusted for 
age at onset, sex, and TDP-43 subtype. Finally, the multivariable mod-
el assessing sex was adjusted for age at death, TDP-43 subtype, and 
genotype. Regression coefficients and 95% CIs were estimated and 
are interpreted as the change in the mean level of truncated or full-
length STMN2 RNA in the frontal cortex (on the base 2 logarithmic 
scale) corresponding to the presence of the given characteristic (cat-
egorical variables) or a specified increase (continuous variables). The 
p–TDP-43 response in the frontal cortex was examined on the base 2 
logarithmic scale in linear regression analysis because of its skewed 
distribution. In order to adjust for the 5 different variables that were 
assessed for association with the separate truncated and full-length 
STMN2 RNA outcomes, we used Bonferroni’s correction for multiple 
testing, after which P values of less than 0.01 were considered statis-
tically significant. All statistical tests were 2 sided. All statistical anal-
yses described above were performed using R Statistical Software, 
version 3.6.2 (R Foundation for Statistical Computing).
Statistical analyses for iPSC studies and qRT-PCR of RNA extract-
ed from human tissues were performed using GraphPad Prism 8 
(GraphPad Software), in which 1-way ANOVA with Bonferroni’s 
post hoc test was performed for multiple group comparisons, and an 
unpaired Student t test was performed when only 2 groups were com-
pared. The statistical test and number of independent experiments 
used for each analysis are indicated in the figure legends.
Study approval. The NYGC ALS Consortium samples presented in 
this work were acquired through various IRB protocols from member 
sites and the Target ALS postmortem tissue core and transferred to the 
NYGC in accordance with all applicable foreign, domestic, federal, state, 
and local laws and regulations for processing, sequencing, and analyses.
Postmortem brain tissues from patients with FTLD-TDP or PSP 
and from cognitively normal individuals were obtained from the Mayo 
Clinic Florida Brain Bank. Diagnosis was independently ascertained 
by trained neurologists and neuropathologists upon neurological and 
pathological examinations, respectively. Written informed consent 
was given by all participants or authorized family members, and all 
protocols were approved by the IRB and ethics committee of the Mayo 
Clinic. A summary of the patients’ characteristics is provided in Table 1. 
RNA extraction and NanoString analyses in postmortem tissues. 
Using the RNAeasy Plus Mini Kit (QIAGEN), RNA was extracted 
from frozen human postmortem frontal cortex tissues (33). RNA 
with a RIN of 7.0 or higher, as determined using an Agilent 2100 
bioanalyzer (Agilent Technologies), was used to measure transcript 
levels using the NanoString PlexSet platform (250 ng human brain 
RNA, according to the manufacturer’s instructions). Transcript lev-
el abundance was determined using nSolver 4.0 software (Nano-
String Technologies) and normalized to HTRP1, a housekeeping 
gene that was unaltered across disease subtypes in our data set 
and previously used to normalize human brain transcripts (71). The 
sequences of the NanoString probes used in this study are included 
in Supplemental Table 5.
p–TDP-43 immunoassay. The p–TDP-43 immunoassay was per-
formed as previously described (33). Briefly, approximately 50 mg 
postmortem tissue from the frontal cortex of patients or unaffect-
ed individuals were homogenized in cold RIPA buffer (25 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 1% sodium deoxycholate, 1% Nonidet 
P-40, 0.1% sodium dodecyl sulfate, and protease and phosphatase 
inhibitors) and sonicated on ice. Homogenates were centrifuged at 
100,000g for 30 minutes at 4°C. The supernatant was collected, and 
the pellet was resuspended in RIPA buffer, sonicated and centrifuged 
again to prevent carryover of soluble material. The RIPA-insoluble 
pellet was extracted using 7 M urea buffer and then sonicated and 
centrifuged at 100,000g for 30 minutes at 22°C. The protein concen-
tration of the urea-soluble supernatant was determined by Bradford 
assay. p–TDP-43 levels were determined using a sandwich Meso Scale 
Discovery (MSD) immunoassay. The capture antibody was a mouse 
monoclonal antibody that detects TDP-43 phosphorylated at serines 
409/410 (1:500, no. CAC-TIP-PTD-M01, Cosmo Bio USA), and the 
detection antibody was a sulfo-tagged rabbit polyclonal C-terminal 
TDP-43 antibody (2 μg/mL, 12892-1-AP, Proteintech). Urea-solu-
ble fractions were diluted in TBS to 35 μg protein per well and test-
ed in duplicate wells. Response values corresponding to the intensity 
of emitted light upon electrochemical stimulation of the assay plate 
using the MSD QUICKPLEX SQ120 were acquired.
Statistics. Comparisons of truncated STMN2 RNA in the frontal 
cortex between the separate non–FTLD-TDP groups of controls and 
patients with PSP and various groups of patients with FTLD-TDP 
(all FTLD-TDP patients as well as 4 different subgroups according 
to the TDP-43 subtype) were made using single-variable (i.e., unad-
justed) and multivariable linear regression models. Multivariable 
models were adjusted for age at death, sex, and RIN, and truncated 
STMN2 RNA in the frontal cortex was examined on the base 2 log-
arithmic scale, owing to its skewed distribution. Regression coeffi-
cients (referred to as β) and 95% CIs were estimated and interpreted 
as the difference in mean truncated STMN2 RNA levels in the frontal 
cortex (on the base 2 logarithmic scale) between the given group of 
FTLD-TDP patients and the given reference group (cognitively nor-
mal controls or patients with PSP). Additionally, to further assess the 
ability of truncated STMN2 RNA in the frontal cortex to discriminate 
between FTLD-TDP and non–FTLD-TDP individuals (again, sep-
arately for cognitively normal controls and patients with PSP), we 
estimated the area under the ROC curve (AUC); an AUC of 0.5 corre-
sponded to the predictive ability equal to that of chance, whereas an 
AUC of 1.0 indicated perfect predictive ability. Bonferroni’s correc-
tion was applied to adjust for the 5 different statistical tests that were 
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